Year: 2025

The Jackson Laboratory acquires New York Stem Cell Foundation to transform biomedical research and accelerate precision therapies for patients

New integrated platform will transform early-stage research, equipping scientists worldwide to uncover disease mechanisms earlier and advance progress toward therapies...

PointClickCare Announces New AI-Powered Solution and Unveils Bold New Brand, Reinforcing Commitment to Exceptional Care and Innovation

Latest AI-powered innovation, Chart Advisor, empowers providers to proactively manage risks and transform care delivery TORONTO, Oct. 20, 2025 /PRNewswire/...

A Measles Drug with Strong Activity without Toxicity Can Be Available Now for Emergency Use, Says NanoViricides – NV-387 Broad-Spectrum Antiviral with Activity Against Measles Virus

SHELTON, CT / ACCESS Newswire / October 20, 2025 / NanoViricides, Inc., a publicly traded company (NYSE American:NNVC) (the "Company"),...

HLTH 2025: 150 Past Attendees and Investors Identify Their Five AI Platform Categories Set to Displace Legacy Health IT in 2026

Compiled by Black Book Research from VC PE and banking investors, the briefing ranks which AI-driven categories are converting pilots...

ADARx Pharmaceuticals Announces Clinical Data Presentation at the American Society of Nephrology (ASN) Kidney Week 2025

SAN DIEGO, Oct. 20, 2025 (GLOBE NEWSWIRE) -- ADARx Pharmaceuticals, Inc. (ADARx), a late-stage clinical biotechnology company developing next-generation RNA...

Palisade Bio Announces First Patients Dosed in Phase 1b Study of Oral First-In-Class PDE4 Inhibitor Prodrug, PALI-2108, for the Treatment of Fibrostenotic Crohn’s Disease (FSCD)

First dual-acting anti-inflammatory and anti-fibrotic candidate in development for FSCD, a condition with no approved therapies Topline safety, PK, and...

error: Content is protected !!